Relevant conflicts of interest/financial disclosures: Nothing to report Full financial disclosures and author roles can be found in the online version of this article.
Long-term follow-up of botulinum toxin therapy for focal hand dystonia: Outcome at 10 years or more†
Article first published online: 1 FEB 2011
Copyright © 2011 Movement Disorder Society
Volume 26, Issue 4, pages 750–753, March 2011
How to Cite
Lungu, C., Karp, B. I., Alter, K., Zolbrod,, R. and Hallett, M. (2011), Long-term follow-up of botulinum toxin therapy for focal hand dystonia: Outcome at 10 years or more. Mov. Disord., 26: 750–753. doi: 10.1002/mds.23504
- Issue published online: 19 APR 2011
- Article first published online: 1 FEB 2011
- Manuscript Accepted: 3 OCT 2010
- Manuscript Revised: 23 JUL 2010
- Manuscript Received: 29 APR 2010
- focal hand dystonia;
Previous studies have explored the efficacy and safety of botulinum neurotoxin (BoNT) treatment for Focal hand dystonia (FHD), but none have followed a large number of patients for 10 years or more.
Retrospective study, with benefit and weakness assessed on a 0 to 4 subjective scale. Demographic, clinical and treatment characteristics were analyzed using t tests and Pearson correlations.
Twenty FHD patients had 10 years or longer treatment. Interinjection intervals were variable. Musicians were more likely to wait longer between injections and had less complex dystonia. There was a trend for larger benefit in women and with shorter intervals. The dose increased over time. Dystonia characteristics did not predict response or side-effects, but benefit magnitude predicted longer compliance. No serious side-effects or antibody-mediated resistance occurred.
This is the longest reported period of BoNT treatment in the largest FHD cohort. BoNT therapy for FHD remains safe and effective after more than a decade of treatment. © 2011 Movement Disorder Society